Epitope-based Vaccines (Smallpox, Tularemia, TB, H. Pylori, Influenza)
EpiVax employs a “Gene-to-Vaccine” design approach for the development of biodefense vaccines against potential bio-warfare agents. Epitopes provide the information required to trigger a protective immune response. The suite of computational tools (EpiMatrix, Conservatrix, etc.) identifies T cell epitopes of interest to validate in vitro and in vivo, for use in final vaccine constructs. Several epitope-based vaccines are being developed, including Smallpox, Tularemia, TB, H. Pylori, and Influenza.
Availability: In Development
| Manufacturer |
| EpiVax, Inc. |
| Product Name |
| Epitope-based Vaccines (Smallpox, Tularemia, TB, H. Pylori, Influenza) |
| Detection Category |
| Biological |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| EpiVax employs a “Gene-to-Vaccine” design approach for the development of biodefense vaccines against potential bio-warfare agents. Epitopes provide the information required to trigger a protective immune response. The suite of computational tools (EpiMatrix, Conservatrix, etc.) identifies T cell epitopes of interest to validate in vitro and in vivo, for use in final vaccine constructs. Several epitope-based vaccines are being developed, including Smallpox, Tularemia, TB, H. Pylori, and Influenza. |
| Availability |
| In Development |
| Technology Readiness Level (TRL) |
| 6 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Weight |
| <1 lb. |
| Power Requirements |
| None |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Smallpox, Tularemia, TB, H. Pylori, and Influenza |
| Operating Time |
| Preventative administration prior to exposure |
| Training Required |
| <1 day training |
